Original Article

You have full text access to this OnlineOpen article

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial

  1. H C Bodenheimer Jr,
  2. K L Lindsay,
  3. G L Davis,
  4. J H Lewis,
  5. S N Thung,
  6. L B Seeff

Article first published online: 30 DEC 2003

DOI: 10.1002/hep.510260231

Issue

Hepatology

Hepatology

Volume 26, Issue 2, pages 473–477, August 1997

Additional Information

How to Cite

Bodenheimer, H. C., Lindsay, K. L., Davis, G. L., Lewis, J. H., Thung, S. N. and Seeff, L. B. (1997), Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology, 26: 473–477. doi: 10.1002/hep.510260231

Author Information

  1. Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029-6504, USA

Publication History

  1. Issue published online: 30 DEC 2003
  2. Article first published online: 30 DEC 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (162K)

References

  • 1
    Alter MJ, Margolis HS, Krawczynski K, Judson EN, Mares A, Alexander J, Hu PY, et al. The natural history of community–acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899–1905.
  • 2
    Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inque O, Hashimoto E, et al. The long–term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334–1340.
    Direct Link:
  • 3
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled trial. N Engl J Med 1989; 321: 1501–1506.
  • 4
    DiBisceglie A, Martin P, Kassianides C, Lisker–Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon–alfa therapy for chronic hepatitis C: a randomized, double–blind, placebo–controlled trial. N EnglJ Med 1989; 321: 1506–1510.
  • 5
    Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, et al. Comparison of 1 or 3 MU of interferon alfa–2b and placebo in patients with chronic non–A, non–B hepatitis. Gastroen–terology 1991; 101: 497–502.
  • 6
    Saracco G, Rosina F, Torrani–Cerenzia MR, Lattore V, Chiandussi L, Gallo V, Petrino R, et al. A randomized controlled trial of interferon alfa–2b as therapy for chronic non–A, non–B hepatitis. J Hepatol 1990; 11: S43–S49.
  • 7
    DiBisceglie AM, Shindo M, Fong T–L, Fried MW, Swain MG, Bergasa NV, Axiotis CA, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649–654.
    Direct Link:
  • 8
    Reichard O, Anderson J, Weiland O. Schvarcz. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 1058–1061.
  • 9
    Reichard O, Anderson J. Ribavirin: a possible alternative for the treatment of chronic non–A, non–B hepatitis. Scand J Infect Dis 1990; 22: 509.
  • 10
    Shindo M, DiBisceglie AM, Cheung L, Shih W–K, Cristiano K, Feinstone SM, Hoofnagle JH. Decrease in serum hepatitis C viral RNA during alpha–interferon therapy for chronic hepatitis C. Ann Intern Med 1991; 115: 700–704.
  • 11
    Stayver L, Rossaur R, Wyseur AN, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characteristics of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093–1102.
  • 12
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431–435.
    Direct Link:
  • 13
    Rodriguez WJ, Parrott RH. Ribavirin aerosol treatment of serious respiratory syncytial virus infection in infants. Infect Dis Clin North Am 1987; 1: 425–439.
  • 14
    Patterson J, Fernandez–Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990; 12: 1139–1146.
  • 15
    Allen L, Huffman JH, Sidwell RW. Failure of 1–b–D–ribofuranosyl–l, 2, 4–triazole–3–carboxamide (virazole, ICN 1229) to stimulate interferon. Antimicrob Ag Chemother 1973; 3: 534–535.
  • 16
    Reichard O, Yun Z–B, Sönnerborg A, Weiland O. Hepatitis C viral RNA liters in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993; 22: 1–4.
  • 17
    DiBisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double–blind, placebo–controlled trial. Ann Intern Med 1995; 123: 897–903.
  • 18
    Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993; 105: 507–512.
  • 19
    Camps J, Garcia N, Riezu–Boj JI, Civeira MP, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol 1993; 19: 408–412.
  • 20
    Ning Q, Brown D, Parodo J, Cattral M, Fung L, Liu M, Rotstein O, et al. Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1 and procoagulant activity and preserves TH11 cytokine production, but inhibits TH2 cytokine response. Hepatology 1996; 24: 355A.
  • 21
    Regenstein F, Towbin B. Viral hepatitis: the emerging role of antiviral drugs. Drug Therapy 1993; 93: 29192–29200.
  • 22
    Brillanti S, Masci C, Miglioli M, Barbara L. Combination therapy with ribavirin and α–interferon in patients with chronic hepatitis C resistant to a–interferon treatment. α. Gastroenterology 1994; 107: 812–817.
Get PDF (162K)